Open AccessTemporary Ovarian Suppression With Gonadotropin‐Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate?
Author(s) -
Del Mastro Lucia,
Lambertini Matteo
Publication year - 2015
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2015-0373
Subject(s) - medicine , agonist , gonadotropin releasing hormone agonist , fertility , gonadotropin , chemotherapy , hormone , oncology , gonadotropin releasing hormone , fertility preservation , gynecology , endocrinology , luteinizing hormone , receptor , population , environmental health
Temporary ovarian suppression with gonadotropin‐releasing hormone agonist during chemotherapy might be a reliable strategy not only to preserve ovarian function but also to increase the likelihood of becoming pregnant after the end of cytotoxic therapy. The findings of Blumenfeld et al. are consistent with recent data suggesting the efficacy of this strategy in preserving fertility.